Fore Biotherapeutics · Regulatory · plixorafenib (PLX120-03 / FORTE)

CNS Histology Evidence Suite — Dashboard

Programme: BRAF/MAPK-altered CNS tumours Updated: 11 Aug 2026 Status: Working drafts — none submission-ready Classification: Internal — Confidential

What this suite is

Six linked documents supporting CTD Module 2.5.1, Product Development Rationale, under ICH M4E(R2). One consolidated rationale, one traceability register, and four disease-background references covering five histologies. Every figure in the rationale traces through the register to a named primary source and its exact location.

Read order: the rationale is the argument; the register is how it is checked; the histology documents are the evidence beneath it.

⚠ Decision support — not medical or regulatory advice. All six documents are working drafts. Ten open items and two strategic decisions remain (§4, §5). Medical + regulatory HITL review required before any external use. The embargoed SNO-2026 CNS reinterpretation is excluded from every document by design.

1 · At a glance

7
Documents
1 rationale · 1 register · 4 disease references · 1 CFO summary
5
Histologies
DLGNT · PXA · PA · GBM · eGBM
59
Distinct sources
40 PMIDs · 16 NCTs · 3 DOIs, from 96 citation-bearing elements
45
Matrix cells assessed
5 histologies × 9 overview sections (§3)
10
Open items
3 blocking external use (§4)
2
Strategic decisions
Not editorial — require a programme call (§5)

2 · The documents

CTD Module 2.5.1 · the argument

Product Development Rationale — BRAF/MAPK-Altered CNS Tumours

The consolidated rationale: therapeutic context, disease background across all five histologies, current options and their limitations, the cross-histology unmet-need table, and the scientific rationale for plixorafenib. Written to ICH M4E(R2).
2.5.1.1 – 2.5.1.65 histologiesUnmet-need matrixRegulatory precedent
Open →
Traceability · how it is checked

Consolidated Citation Register & Traceability Matrix

One row per distinct source across all documents, mapped to the 2.5.1 claim it supports, with verification status. Records eight material corrections the reconciliation produced, eight unassigned-source dispositions, and every contested figure.
59 sources7 claim codes8 corrections10 contested items
Open →
Disease reference · DLGNT + PXA

DLGNT & PXA — Clinical-Development Summary, Citation-Gap Analysis & References

Slide-by-slide verification of the source deck's claims against primary sources, each pinned to its exact location, plus a second pass across regulatory, trial, conference and competitive sources. The deepest document in the suite.
9 gap rows78 reference entries16 NCT registrations26 competitive items
Open →
Disease reference · pilocytic astrocytoma

Pilocytic Astrocytoma — Summary & References

Full §1–§9 overview plus prognosis, molecular risk and treatment landscape. Carries the BRAF V600E prognostic data, transformation risk, and the only histology in the suite with an already-approved BRAF-targeted competitor.
10-yr PFS 27% vs 60.2%Transformation 2.9%A9952 P = 0.10
Open →
Disease reference · GBM + eGBM

GBM & eGBM — Histology Overview

§A1–A9 for glioblastoma IDH-wildtype, §B1–B9 for the epithelioid morphology, and §C the eGBM/PXA differential — the boundary problem created by adding eGBM alongside the deck's existing PXA section.
GBM V600E ~1%eGBM V600E ~50%eGBM mOS 10 mo7 tables
Open →
Finance & IT · the business case

Regulatory Evidence Platform — CFO Summary

What the suite delivered, the eight material corrections it found in our own working material, and why the operating model supports Regulatory without added headcount. Cost inputs are unfilled assumptions pending Finance.
8 corrections3-part cost model6 risks5 recommendations
Open →
Method · coverage analysis

GBM & eGBM — Reference-Coverage Analysis

Which sections the supplied GBM reference list can and cannot support, section by section. Established that the folder's only BRAF-in-glioblastoma reference contains no epithelioid GBM at all.
GBM 7/1/2eGBM 0/2/84 refs verified
Open →

3 · Coverage matrix — 5 histologies × 9 overview sections

Whether each histology's section is written and adequately sourced. Assessed against the structure the source deck uses for DLGNT and PXA.

✓ Covered — written and primary-sourced ~ Partial — written but thin, review-grade or single-source ✕ Gap — no adequate source
Histology Descrip­tionSub­typesLocali­zationImaging Epidemi­ologyGeneticsGradingWHO criteriaCheck­list
DLGNT ✓Covered ✓Covered ✓Covered ✓Covered ✓Covered ✓Covered ~Partial ✓Covered ✓Covered
PXA ✓Covered ✓Covered ✓Covered ✓Covered ✓Covered ✓Covered ✓Covered ✓Covered ✓Covered
Pilocytic astrocytoma ✓Covered ~Partial ✓Covered ✕Gap ~Partial ✓Covered ✓Covered ✓Covered ✓Covered
Glioblastoma IDH-wt ✓Covered ✓Covered ~Partial ~Partial ✓Covered ✓Covered ✓Covered ✓Covered ✓Covered
Epithelioid GBM ✓Covered ✕Gap ✓Covered ✕Gap ✓Covered ✓Covered ✓Covered ✕Gap ✓Covered
Reading the gaps. Imaging is the systematic weakness — a gap or partial in three of five histologies, and the only section with no adequate source anywhere for PA and eGBM. eGBM's three gaps are structural, not clerical: it has no defined subtypes and is not a listed WHO 2021 entity, so those cells cannot be closed by finding a better reference — they require a decision on how eGBM is defined operationally. DLGNT's grading is marked partial because DLGNT is not formally graded in WHO 2021.

4 · Open items

ItemSeverityWhereAction required
Plixorafenib CNS denominatorsBlockingRegister §3Three cuts with different denominators — 6/10 (SNO 2023), 9 evaluable (de la Fuente 2024), n=113 (SNO 2024) — including two different "67%" figures. Fix which population any quoted ORR refers to and always state the denominator.
⚠-flagged conference & agency itemsBlockingRegister §1.4–1.6AACR 2025 CT247, AACR 2026 CT154, ASCO 2026 abstr 10031, belvarafenib registration, PRV sunset status. Publisher and agency pages blocked automated fetch — manual primary pull required before external use.
Embargo controlBlockingAll documentsSNO-2026 CNS reinterpretation must not enter any document. Published abstracts only. Currently held.
Tovorafenib benchmark figureMedium2.5.1.3.3Use the approval figures (ORR 51%, mDOR 13.8 mo); cite the 67%/16.6-mo cut only with its source identified. Corrected — do not reintroduce.
GBM localization & imagingMediumOverview §A3, §A4Rest entirely on a review-grade source. Replace with primary references.
PA imaging, incidence, sexMediumPA §4, §5No source at all for imaging; no incidence or sex figure. A registry source would close the latter two.
eGBM entity definitionMediumOverview §CNot a WHO 2021 entity; merges with PXA on methylation. Any subgroup or enrolment claim needs an operational definition separating it from anaplastic PXA.
DLGNT 1q gainMediumReport §2Two studies disagree and are not independent — shared senior authorship, up to ~12 of 30 patients may overlap. Do not present as independent cohorts.
"No approval covers PXA"Medium2.5.1.3.3Restated as "guideline-supported and trial-accessible, but not approved" — PXA is named in dab+tram trial eligibility and positioned by the Rudà 2022 guideline. Corrected.
PDQ reference [27]LowPA §P1Diencephalic 22% vs 52% traceable only through PDQ. Identify the underlying primary.

5 · Strategic decisions — programme calls, not editorial fixes

DecisionWhat the evidence showsWhy it needs a call
Designation vs positioning Breakthrough Therapy designation (1 Apr 2026) is for adult BRAF-V600E high-grade glioma. The programme is positioned paediatric, FORTE enrolls ≥8 years, and no Rare-Pediatric-Disease and no EMA designation were found. A reviewer reading 2.5.1 sees a paediatric rationale resting on an adult designation. Either the positioning or the designation strategy should move — deliberately, not by wording.
Where the programme claims its space Two populations carry the unmet need: fusion-driven disease (PA, DLGNT) mechanistically excluded from approved type I agents, and V600E disease outside the paediatric-LGG label (PXA, eGBM, V600E GBM, adults). Tovorafenib is moving front-line via FIREFLY-2. The fusion space is the mechanistic differentiator but tovorafenib already holds a BRAF-altered paediatric LGG approval and is expanding. The competitive window is narrowing while the rationale is still in draft.

6 · Complete source index

Every source behind the suite, grouped as it appears in the corpus. 65 distinct works — 51 from the DLGNT/PXA reference list plus 14 added by the GBM, eGBM and pilocytic-astrocytoma work. Claim-level mapping and verification status live in the citation register.

6.1 · Citation accounting

MeasureCountWhat it is
Citation-bearing elements (DLGNT/PXA report)9678 listed reference entries + 9 gap-table rows + 9 detail modals
Listed reference entries78§3.1–3.3 (34) + §5.1–5.5 (17) + §5.6 competitive landscape (26), less one duplicated heading row
Distinct reference works — corpus51After grouping each entry to one work
Distinct reference works — added14GBM/eGBM and pilocytic-astrocytoma sources not in the corpus
Total distinct works65The unit that matters — a work may carry PMID + PMCID + DOI
Identifier strings across the corpus6840 PMIDs · 16 NCTs · 9 PMCIDs · 3 DOIs — over-counts works, since PMCIDs and DOIs alias papers already held by PMID
Corpus works carried into the analysis51 / 51 (100%)Verified programmatically at work level — see the note below
How "carried" was tested, and what it does and does not mean. Each of the 51 corpus works was matched against the citation register and the five other documents by any of its identifiers, falling back to author-surname match for the 6 works that carry no identifier. All 51 resolve. That confirms every source is accounted for and dispositioned — it does not mean all 51 support a 2.5.1 claim. Eight source groups are formally marked Unassigned in the register with a recommended disposition (promote, retire, or move to Module 4 / 2.7), and those dispositions are the honest status of that material.

6.2 · DLGNT — core literature (13)

  1. Rodriguez FJ, et al. Disseminated oligodendroglial-like leptomeningeal tumor of childhood. Acta Neuropathol. 2012;124(5):627–641. PMID 22941225.
  2. Deng MY, et al. Molecularly defined DLGNT comprises two subgroups with distinct clinical and genetic features. Acta Neuropathol. 2018;136(2):239–253. PMID 29766299.
  3. Chiang J, et al. Prognostic significance of chromosome arm 1q gain and methylation class in DLGNT. Acta Neuropathol. 2022;144(6):1185–1187. PMID 36175668.
  4. Lee C, et al. DLGNT: a systematic review highlighting molecular heterogeneity and survival outcome. Cancers (Basel). 2026;18(6):912. DOI 10.3390/cancers18060912.
  5. WHO Classification of Tumours Editorial Board. Central Nervous System Tumours, 5th ed. IARC; 2021.
  6. Mikkelsen MK, et al. DLGNT: a comprehensive clinical and molecular analysis. Acta Neuropathol. 2025;150(1):18. PMID 40788548.
  7. Jiang H, et al. Clinical progression, pathological characteristics, and radiological findings in children with diffuse leptomeningeal glioneuronal tumors: a systematic review. Front Oncol. 2022;12:970076. PMID 36185310.
  8. de los Reyes-Nabhan NK, et al. Diffuse leptomeningeal glioneuronal tumor in adults: case report and literature review. Case Rep Oncol. 2024;17(1):337–343. PMID 38404404.
  9. Manoharan N, et al. DLGNT in children: the emerging role of genomic analysis. Acta Neuropathol Commun. 2021;9(1):147. PMID 34493325.
  10. Messiaen J, et al. Patient-derived models from a metastatic pediatric DLGNT with KIAA1549::BRAF fusion. Acta Neuropathol. 2022;144(3):585–588. PMID 36107235.
  11. Chun BM, et al. Response to a novel type II RAF inhibitor in DLGNT with BRAF fusion. The Oncologist. 2025;30(5):oyaf093. PMID 40377441.
  12. Castellano-Damaso S, et al. Continuous response on reduced-dose trametinib in relapsed disseminated KIAA1549-BRAF pLGG. Front Oncol. 2024;14:1381354. PMID 38846974.
  13. Selt F, et al. Response to trametinib in progressive pediatric low-grade glioma. J Neurooncol. 2020;149(3):499–510. PMID 33026636.

6.3 · PXA — core literature (10)

  1. Louis DN, et al. The 2021 WHO Classification of Tumors of the CNS: a summary. Neuro-Oncol. 2021;23(8):1231–1251. PMID 34185076.
  2. Phillips JJ, et al. The genetic landscape of anaplastic PXA. Brain Pathol. 2019;29(1):85–96. PMID 30051528.
  3. Giannini C, et al. Pleomorphic xanthoastrocytoma: what do we really know about it? Cancer. 1999;85(9):2033–2045. PMID 10223246.
  4. Ida CM, et al. Pleomorphic xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol. 2015;25(5):575–586. PMID 25318587.
  5. Schindler G, et al. BRAF V600E mutation in 1,320 nervous-system tumors. Acta Neuropathol. 2011;121(3):397–405. PMID 21274720.
  6. Weber RG, et al. Frequent CDKN2A/CDKN2B homozygous deletion in PXA. Oncogene. 2007;26(7):1088–1097. PMID 16909113.
  7. Ma C, et al. BRAF V600E, TERT, and IDH2 in PXA: a large case series. World Neurosurg. 2018;120:e1225–e1233. PMID 30240866.
  8. Vaubel R, et al. Biology and grading of PXA. Brain Pathol. 2021;31(1):20–32. PMID 33368753.
  9. Mahajan S, et al. The evolution of PXA: genesis to molecular alterations and mimics. Lab Invest. 2022;102(7):670–681. PMID 35031693.
  10. Dampier CH, et al. Methylation-class PXA: analysis of 469 tumors. Neuro-Oncol Adv. 2025;7(1):vdaf089. DOI 10.1093/noajnl/vdaf089.

6.4 · Therapeutic context — RAF/BRAF-targeted therapy & plixorafenib (11)

  1. de la Fuente M, et al. Safety & efficacy of plixorafenib (FORE8394/PLX8394) in BRAF-altered primary CNS tumors [TRLS-02]. Neuro-Oncology. 2024;26(Suppl 4). NCT02428712.
  2. de la Fuente MI, et al. FORE8394 in advanced solid and CNS tumors: phase 1/2a results. J Clin Oncol. 2023;41(16_suppl):3006. NCT02428712.
  3. Rosen E, et al. FORTE: a phase 2 master protocol assessing plixorafenib for BRAF-altered cancers. J Clin Oncol. 2025;43(16_suppl):TPS2091. NCT05503797.
  4. Kilburn LB, et al. Type II RAF inhibitor tovorafenib in R/R pediatric low-grade glioma: FIREFLY-1. Nat Med. 2024;30(1):207–217. PMID 37978284. NCT04775485.
  5. Singh S, et al. FDA Approval Summary: tovorafenib for R/R BRAF-altered pediatric LGG. Clin Cancer Res. 2025;31(8):1383–1389. PMID 39808502.
  6. Bouffet E, et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med. 2023;389(12):1108–1120. PMID 37733309. NCT02684058.
  7. Hargrave DR, et al. Dabrafenib plus trametinib in R/R BRAF V600 pediatric high-grade glioma. J Clin Oncol. 2023;41(33):5174–5183. PMID 37643378.
  8. Wen PY, et al. Dabrafenib plus trametinib in BRAF V600E low- and high-grade glioma (ROAR). Lancet Oncol. 2022;23(1):53–64. PMID 34838156.
  9. Kaley T, et al. BRAF inhibition in BRAF-V600 gliomas: VE-BASKET. J Clin Oncol. 2018;36(35):3477–3484. PMID 30351999.
  10. Brown NF, et al. Dabrafenib in BRAF-V600 anaplastic PXA. CNS Oncol. 2017;6(1):5–6. PMID 27781490.
  11. Chamberlain MC. Salvage BRAF inhibitors for recurrent PXA: a retrospective case series. J Neurooncol. 2013;114(2):237–240. PMID 23756727.

6.5 · Regulatory (FDA / EMA) (4)

  1. Plixorafenib — FDA designations: ✓ Fast Track (Sep 2022, BRAF Class 1/2); ✓ Orphan Drug (Mar 2023, primary brain & CNS malignancies); ✓ Breakthrough Therapy (1 Apr 2026, adult BRAF-V600E high-grade glioma — "first BTD for a targeted therapy in HGG").
  2. Tovorafenib (OJEMDA): ✓ FDA accelerated approval 23 Apr 2024 — pediatric LGG with BRAF fusion/rearrangement or V600 (ORR 51%, mDOR 13.8 mo; FIREFLY-1). ✓ EMA conditional MA 22 Apr 2026 (Ipsen; same indication; confirmatory FIREFLY-2).
  3. Dabrafenib + trametinib: ✓ FDA pediatric LGG BRAF-V600E (16 Mar 2023; ORR 46.6% vs 10.8%); ✓ EMA Finlee/Spexotras (15 Nov 2023, with an explicit pediatric HGG V600E indication); ✓ FDA tissue-agnostic BRAF-V600E solid tumors (22 Jun 2022) — the histology-agnostic template.
  4. Pathway precedents: RACE for Children Act (BRAF is on FDA's pediatric molecular-target list); tissue-agnostic framework; Rare-Pediatric-Disease designation + priority-review voucher (⚠ program authorization sunset ~Dec 2024, reauthorization pending — verify); EMA PIP mandatory + conditional-MA criteria. Vemurafenib has no CNS/glioma indication (melanoma/ECD only).

6.6 · Clinical trials (ClinicalTrials.gov) (4)

  1. Plixorafenib: FORTE NCT05503797 (Ph2 pivotal, recruiting — Sub-A BRAF-fusion CNS, Sub-B V600E glioma/glioneuronal, ≥8 y); NCT02428712 (Ph1/2a, completed); NCT06610682 — plixorafenib ± retifanlimab, CSF-ctDNA endpoint, V600E glioma (Johns Hopkins).
  2. Tovorafenib: FIREFLY-1 NCT04775485; FIREFLY-2/LOGGIC NCT05566795 (Ph3 front-line vs chemo); NCT07206849 (HGG/DIPG expansion); combos (vinblastine NCT06381570), craniopharyngioma NCT05465174, LCH NCT05828069, EAP NCT05760586.
  3. Dab+tram: NCT02684058 (PXA explicitly named in eligibility); NCT03919071 (HGG, anaplastic PXA named); NCT03975829 (rollover).
  4. Competitors in CNS: belvarafenib CNS Ph2 NCT07688356 (BRAF-altered brain tumors — closest CNS competitor; ⚠ investigator-initiated, 2025-registered); PF-07799933 NCT05355701 (Pfizer brain-penetrant pan-mutant BRAF ± binimetinib).

6.7 · Conference readouts — verify before external use (4)

  1. ✓ Plixorafenib, SNO 2023 (CTNI-76): V600+ primary-CNS tumors n=10 — ORR 60% (6/10), HGG 67%, mPFS 34.1 mo (PMC10639671).
  2. ✓ Plixorafenib, SNO 2024 (TRLS-02) — n=113 incl. 5 children; V600E ORR 67%, mDOR 13.9 mo; no pediatric DLTs (PMC11182979). ✓ ASCO 2023 abstr 3006 (already cited). ⚠ AACR 2025 CT247 (FORTE design); AACR 2026 CT154 (V600 CRC ORR 8%).
  3. ✓ Tovorafenib, SNO 2024 (CTNI-09): FIREFLY-1 drug-holiday — 24/26 stayed off-treatment (durability-after-stopping); NCOG-05 HRQoL stable. Nysom 2025 optic-pathway subgroup (PMID 39700439).
  4. ✓ Dab+tram, ASCO 2022 LBA2002 (LGG debut). ⚠ ASCO 2026 abstr 10031 — pediatric MAPKi long-term follow-up (numbers unverified).

6.8 · DLGNT — additional literature (2)

  1. ✓ Campanelli 2025, Acta Neuropathol Commun 13:208 (DOI 10.1186/s40478-025-02100-1).
  2. ✓ De Carli 2026 (Cancers 18(4):549); Witten 2024 (PMID 39073721); de los Reyes-Nabhan 2024 (PMID 38404404, adult onset); Torres-Rey 2023 (PMID 38034149, MMR / aggressive); Giantini Larsen 2023 SNO METB-07 (CSF cfDNA detected KIAA1549::BRAF 5/7).

6.9 · PXA — additional literature (3)

  1. ✓ Vaubel 2018 (PMID 28181325) — CDKN2A/B deletion the dominant recurrent CNA; ✓ Vizcaino 2024 (PMID 39042515) — CDKN2A homozygous deletion in >90% of PXA.
  2. ✓ Vaubel 2021 (21% anaplastic at diagnosis; 5-yr OS 80.8% vs 47.6%); ✓ Zuo 2023 (PMID 37448517, high-grade PXA 5-yr OS 51.5%); ✓ Sullivan 2024 (grade-3 aggressive).
  3. ✓ Rudà 2022 EANO/EURACAN/SNO guideline (PMID 35908833) positions BRAF/MEK inhibitors for BRAF-altered PXA; ✓ Kata 2022 (PMID 36351333, dab+tram series), Migliorini 2017 (PMID 28235815), Inoue 2024 (PMID 39640311).

6.10 · Added by the GBM, eGBM & pilocytic-astrocytoma work (14)

  1. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other CNS Tumors Diagnosed in the United States in 2014–2018. Neuro Oncol. 2021;23(12 Suppl 2):iii1–iii105. PMID 34608945; PMC8491279.
  2. Guo X, Gu L, Li Y, et al. Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification. Front Oncol. 2023;13:1200815. PMID 37483487; PMC10358772.
  3. McNulty SN, Schwetye KE, Ferguson C, et al. BRAF mutations may identify a clinically distinct subset of glioblastoma. Sci Rep. 2021;11:19999. PMID 34625582; PMC8501013.
  4. Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol. 2013;37(5):685–698. PMID 23552385.
  5. Wang S, He Q, Zhang Q, Guan B, Zhou X. Clinicopathologic features and prognosis of epithelioid glioblastoma. Int J Clin Exp Pathol. 2020;13(7):1529–1539. PMID 32782671.
  6. Korshunov A, et al. Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathol. 2018. PMID 28990704.
  7. Behling F, Barrantes-Freer A, Skardelly M, et al. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn Pathol. 2016;11:55. PMID 27350555.
  8. Grochans S, et al. / StatPearls: Glioblastoma Multiforme. StatPearls [Internet]. NCBI Bookshelf NBK558954. Bookshelf NBK558954.
  9. de Blank P, Bandopadhayay P, Haas-Kogan D, Fouladi M, Fangusaro J. Management of pediatric low-grade glioma. Curr Opin Pediatr. 2019;31(1):21–27.
  10. PDQ Pediatric Treatment Editorial Board. Childhood Astrocytomas and Other Gliomas Treatment (PDQ®) — Health Professional Version. National Cancer Institute. Updated April 14, 2025. cancer.gov.
  11. Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol. 2012;30(21):2641–2647.
  12. U.S. Food and Drug Administration. FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation. March 16, 2023.
  13. Lassaletta A, Zapotocky M, Mistry M, et al. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. J Clin Oncol. 2017;35(25):2934–2941. DOI 10.1200/JCO.2016.71.8726.
  14. Mistry M, Zhukova N, Merico D, et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015;33(9):1015–1022.

6.11 · Competitive & resistance landscape (26 items)

Held as a narrative block in the corpus rather than a reference list — class mechanism (type I → type II → paradox-breaker), the pan-RAF competitor pack, PF-07799933, resistance mechanisms and positioning. Rebuilt into §2.5.1.3.3 and §2.5.1.5 during the reconciliation pass. Read in the source report §5.6 →

6.12 · Source material

  1. Glossary — ind_summary_glossary.html DLGNT, PXA, MAPK, methylation class & 40 more terms.
  2. Source deck — "Patient Story Boards — Sub B, A1 CNS, PLX120-03" (M. Winkler, 03 Aug 2026). 8 slides: title, DLGNT ×4, PXA ×3. Contains no GBM, eGBM or PA slides — those overviews were written to its structure, not against existing slide text.
  3. Supplied reference sets — DLGNT Sources.docx · PXA Citations.docx · GBM/GBM references.docx (4 refs) · Pilocytic Astrocytoma Summary Literature Only.docx (4 paragraphs + 5 refs). All read in full; all identifiers verified.
Method & limits. Counts are machine-derived from the documents themselves: 59 distinct source identifiers across 96 citation-bearing elements; 45 matrix cells. Coverage assessments reflect whether a section is written and adequately sourced, not merely present — sections resting on review-grade sources are marked Partial rather than Covered. Severity ratings are carried from the citation register and the rationale's open-items table; ⚠ verification marks originate in the source documents and were not re-verified for this dashboard. All six documents are working drafts and none has been through medical or regulatory review.
💬 Add Comment
💬 Review comments